Novartis ESMO Event Presentation

Ph3 VISION study: Pluvicto met both primary endpoints of rPFS and OS in the mCRPC post-taxane setting, as published in NEJM1 Reduced risk of progression or death by 60% rPFS HR: 0.40 (99.2% CI: 0.29, 0.57), p<0.001 (one-sided) Median rPFS, months: 8.7 vs. 3.4 Reduced risk of death by 38% OS HR: 0.62 (95% CI: 0.52, 0.74), p<0.001 (one-sided) Median OS, months: 15.3 vs. 11.3 Event-free probability (%) 100 90 80 70 60 50 SoC alone 177 Lu-PSMA-617 + SoC 40 30 20 10 0 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Time from randomization (months) Event-free probability (%) 60 40 30 85432 100 90 80 70 50 SoC alone 177 Lu-PSMA-617 + SoC 20 10 0 0 2 4 6 Number still at Risk 177 Lu-PSMA-617+ SoC 385 373 362 292 272 235 215 194 182 146 137 121 88 83 71 51 49 37 21 18 Number still risk SoC alone 196 146 119 58 36 26 19 14 14 13 13 11 7 7 7 4 3 3 2 2 0 6 1 1 0 0 0 0 177Lu-PSMA-617+ SoC 551 535 SoC alone 280 238 506 470 203 173 425 377 332 289 236 166 112 155 133 117 98 22 8 10 12 14 16 18 20 22 Time from randomization (months) 63 24 26 28 30 32 333 51 33 16 33 0 O 0 20 50 15 52 369 865 1. Sartor, N Engl J Med 2021;385:1091-103 6 NOVARTIS ESMO EVENT | OCTOBER 24, 2023 | INVESTOR PRESENTATION NOVARTIS | Reimagining Medicine

View entire presentation